Latest Clinical Validation News

4DMedical has landed a three-year commercial contract with SimonMed Imaging, deploying its CT:VQ™ technology across more than 170 US outpatient centres, marking a significant step in its US market expansion.

TruScreen Group reported a 42% increase in FY2026 sales driven by new market entries including India and Indonesia, alongside launching a large-scale cervical cancer screening program in Vietnam and submitting major UNITAID proposals.

Noxopharm has unveiled new data showing its Sofra technology dramatically boosts TLR8 activation, a key immune pathway, potentially reshaping cancer immunotherapy.

Pacific Edge reported a steep 47% revenue drop in FY26 following Medicare coverage loss but secured a draft Medicare policy covering its Cxbladder tests and raised NZ$25.4 million to fuel growth and commercial execution.

TruScreen Group Limited has kicked off a NZ$2.9 million capital raising combining a NZ$1 million placement and a NZ$1.94 million rights issue to fund its global expansion and regulatory compliance efforts. The company reported a 42% jump in product sales for FY2026 and is targeting major public health programs across 14 countries.

OncoSil Medical has clinched TGA approval for its OncoSil™ device, the first Class III medical device targeting pancreatic tumours in Australia, paving the way for local commercialisation and enhanced patient access.

4DMedical’s CT:VQ™ technology has been clinically validated in a top respiratory journal, showing a leap in patient response rates for lung volume reduction surgery from 46% to 76%, promising improved outcomes and hospital efficiencies.

Lumos Diagnostics advances US commercial rollout of FebriDx with positive reimbursement data and expanded urgent care adoption ahead of the 2027/28 flu season.

Archer Materials progresses its Biosensor platform from alpha to beta prototype, targeting manufacturability and external validation with expanded diagnostic applications including lithium monitoring.

AVITA Medical reported a 4% revenue increase in Q1 2026 with a narrowed net loss, underpinned by a new BARDA contract and promising Cohealyx clinical data. Leadership changes and regulatory approvals support a confident outlook.

Nexsen has secured a strategic partnership with GHK Hospital Limited in Hong Kong, marking a significant step in validating and commercialising its rapid point-of-care diagnostics across North Asia.

Archer Materials is progressing toward demonstrating a working qubit this year while scaling quantum device fabrication from lab prototypes to wafer-scale manufacturing using semiconductor industry standards.